FDA Lifts Clinical Hold on Curis Cancer Drug, Shares Surge

FDA Lifts Clinical Hold on Curis Cancer Drug, Shares Surge

Curis (NASDAQ: CRIS) said today that the FDA has lifted the partial clinical hold on CUDC-427, the experimental cancer drug it licensed from Genentech a few years ago. The FDA's decision takes CUDC-427 out of limbo; Curis can now go ahead and …

8
Like
Save

Comments

Write a comment

*